Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine  

作　　者：Yunlong Cao Xiaohua Hao Xi Wang Qianhui Wu Rui Song Dong Zhao Weiliang Song Yao Wang Ayijiang Yisimayi Wei Wang Juan Du Hongjie Yu Xiaoliang Sunney Xie Ronghua Jin 

机构地区：[1]Changping Laboratory,Beijing,China [2]Biomedical Pioneering Innovation Center(BIOPIC),Peking University,Beijing,China [3]Beijing Advanced Innovation Center for Genomics(ICG),Peking University,Beijing,China [4]National Center For Infectious Diseases,Beijing Ditan Hospital,Capital Medical University,Beijing,China [5]Beijing Key Laboratory of Emerging Infectious Diseases,Institute of Infectious Diseases,Beijing Ditan Hospital,Capital Medical University,Beijing,China [6]School of Public Health,Fudan University,Key Laboratory of Public Health Safety,Ministry of Education,Shanghai,China [7]School of Life Sciences,Peking University,Beijing,China [8]Shanghai Institute of Infectious Disease and Biosecurity,Fudan University,Shanghai,China [9]Department of Infectious Diseases,Huashan Hospital,Fudan University,Shanghai,China

出　　处：《Cell Research》2022年第1期107-109,共3页细胞研究（英文版）

基　　金：financially supported by the Ministry of Science and Technology of China(CPL-1233).

摘　　要：Dear Editor,COVID-19 vaccination campaigns are being conducted in countries worldwide,and 47.4% of the world population has received at least one dose of a COVID-19 vaccine.1 Although vaccination has shaped COVID-19 epidemic curves,waning antibody levels and relatively short-duration protection provided by current COVID-19 vaccines have been observed,especially against SARS-CoV-2 variants of concern(VOCs)and among older individuals.

关 键 词：VACCINATION SHAPED doses 

分 类 号：R186[医药卫生—流行病学]